In conclusion, the findings of this scRNAseq study reveal potential cellular and molecular mechanisms by which systemic treatment of SCF+G-CSF modulates microglia and peripherally derived myeloid cells to mitigate AD pathology in the aged APP/PS1 mouse brain. This evidence concerns the gene APP and Alzheimer disease.